Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous T-cell lymphomas

E H Kaplan1, W T Leslie

  • 1Rush University, Section of Medical Oncology, Chicago, IL 60612.

Current Opinion in Oncology
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Cutaneous T-cell lymphoma (CTCL) is treatable, though often incurable. Advances in understanding and multimodality treatments offer hope for improved long-term survival in early-stage disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating plasma holds in the presence of multiple infections.

IMA journal of mathematics applied in medicine and biology·2002
Same author

Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2001
Same author

Public health consequences of screening patients for adherence to highly active antiretroviral therapy.

Journal of acquired immune deficiency syndromes (1999)·2001
Same author

New approaches to HIV surveillance: means and ends. Summary report of conference held at Yale University, 21-22 May 1998, by the Law, Policy and Ethics Core, Center for Interdisciplinary Research on AIDS, Yale University.

AIDS & public policy journal·2001
Same author

Inner obstacles to psychoanalysts' retirement: personal, clinical, and theoretical perspectives.

Bulletin of the Menninger Clinic·2000
Same author

Treatment on demand: an operational model.

Health care management science·2000
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Cutaneous T-cell lymphoma (CTCL), primarily mycosis fungoides and Sézary syndrome, presents a significant therapeutic challenge.
  • Despite being largely incurable, CTCL is a highly treatable group of hematologic malignancies.
  • The landscape of CTCL therapies is expanding, with ongoing elucidation of treatment mechanisms.

Purpose of the Study:

  • To review the current state of cutaneous T-cell lymphoma treatment.
  • To highlight the importance of multimodality therapy for early-stage disease.
  • To emphasize the need for further research and development in CTCL therapeutics.

Main Methods:

  • Review of existing literature on CTCL therapies.
  • Analysis of current understanding of systemic and topical treatment mechanisms.

Related Experiment Videos

  • Discussion of the role of molecular and cellular diagnostic advancements.

    • Main Results:

    • The number of active therapies for CTCL is increasing.
    • New insights into the mechanisms of systemic and topical treatments are emerging.
    • Multimodality treatment for early-stage CTCL may enhance long-term survival.

    Conclusions:

    • Early intervention with multimodality treatment is crucial for improving outcomes in CTCL.
    • Randomized prospective trials are essential for advancing CTCL treatment strategies.
    • Continued development in molecular genetics and cell-surface phenotyping is key to discovering more effective and specific CTCL therapies.